Covirabio GmbH is a young Start-Up company with the vision to enable pathogen detection and immune monitoring at the Point-of-Care or Point-of-Need. Based on the Covirabio technology platform VERB (Virus Entry Receptor Binding), a portfolio of test systems for the detection of SARS-CoV-2 infections or the immune response to an infection and/or vaccination is currently being developed. For the use at the Point-of-Care or Point-of-Need, the assays are integrated into microfluidic systems. This technology platform is now also expanded to bacterial pathogens.
Company Details
- Employees
- 2
- Founded
- 2020
- Address
- Goethegasse 3, 2/2,austria
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.covirabio.net
- Keywords
- AURIMOD GmbH.
- HQ
- Vienna
Covirabio Gmbh Questions
Covirabio Gmbh's website is http://www.covirabio.net
Covirabio Gmbh's LinkedIn profile is https://at.linkedin.com/company/covirabio
Covirabio Gmbh has
2 employees.
View email and phone details for 2
employees at Covirabio Gmbh.
Covirabio Gmbh's industry is
Biotechnology Research
Covirabio Gmbh's top competitors are
The Blue Box Biomedical Solutions,
Attoquant Diagnostics Gmbh,
Elsee.care,
Bit.bio,
Aeon,
Flinn.ai,
Elyte Diagnostics Gmbh,
Sarmayacar,
Clock.bio,
Aurimod Gmbh.
Covirabio Gmbh's categories are Biotechnology Research
Covirabio Gmbh's founding year is 2020
